Page 3 - Biological E

N440K variant fades as B1617 picks up, say scientists on Covid second wave

The N440K variant of coronavirus,which wreaked havoc during the first wave of the pandemic in the country is diminishing and likely to disappear soon

Biological E to start phase 3 clinical trials of its Covid-19 vaccine soon

The phase III clinical study, to be conducted in 15 sites across India, will evaluate the immunogenicity and safety of Biological E's vaccine candidate in 1,268 healthy subjects

India could get its fourth vaccine by August, says NITI Aayog's V K Paul

Hyderabad-based Biological E's candidate has completed its phase one and two trials and is about to enter stage three

Biological E's Covid-19 vaccine enters Phase I/II trial after DGCI nod

The results of this clinical trial are expected to be available by February 2021, the release said.

We can make over 1.5 bn doses in 2021: Biological E MD & CEO Mahima Datla

Though our target is a billion doses, we may have an upside as we are evaluating various doses in the phase-1 and -2 studies, said Datla

Hyderabad-based Biological E joins hands with J&J for Covid-19 vaccine

The vaccine candidate is in phase 1/2a clinical trials

Biological E ties up with Janssen Pharmaceutica NV for Covid-19 vaccine

Biological E Ltd has entered into an agreement with Janssen Pharmaceutica NV, part of pharma major Johnson & Johnson, for creation and enhancement of production capabilities to manufacture the latter's COVID-19 vaccine. Johnson & Johnson's COVID-19 vaccine candidate (Ad26.COV2.S) is currently in Phase 1/2 a clinical trials, a press release from the city-based vaccine maker said on Thursday. "We are very pleased indeed to collaborate with an organisation like Johnson & Johnson. Given the magnitude of COVID-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration," said Managing Director of BE, Mahima Datla. BE is looking forward to deploying its manufacturing infrastructure to support Johnson & Johnson's commitment to global access to its COVID-19 vaccine, Director of Bio E Holdings Inc, Narender Dev Mantena, who heads .

IFC to back BioE Ltd's pipeline of vaccines, including for Covid-19

The company will raise $30 mn from IFC to support the proposed expansion plan for its pipeline of vaccines and pharma products, besides playing a role in expediting Covid-19 vaccine development

Hyderabad-based Biolegical E opens new Rs 300-crore vaccine facility

Biological E received the authorisation from the Central Drugs Standard Control Organisation for Typhoid conjugate vaccine

Biological E to invest Rs 300 crore on new vaccines plant

The new plant will come up at a special economic zone